We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+3.78%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$151M
AUM Growth
+$23M
Cap. Flow
+$26.2M
Cap. Flow %
17.3%
Top 10 Hldgs %
42.26%
Holding
109
New
25
Increased
23
Reduced
25
Closed
15

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$2.4M
2
PVLA
Palvella Therapeutics
PVLA
+$2.24M
3
ZBIO
Zenas BioPharma
ZBIO
+$2.05M
4
REPL icon
Replimune Group
REPL
+$2.02M
5
TECX
Tectonic Therapeutic
TECX
+$2.01M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$2.14M
2
GILD icon
Gilead Sciences
GILD
+$1.31M
3
THC icon
Tenet Healthcare
THC
+$1.21M
4
SWTX
SpringWorks Therapeutics
SWTX
+$1.12M
5
BPMC
Blueprint Medicines
BPMC
+$994K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
1
LENZ Therapeutics
LENZ
$162M
$28.6M 18.91%
977,245
– –
LLY icon
2
Eli Lilly
LLY
$1.05T
$7M 4.62%
8,976
-440
-5% -$342K
UNH icon
3
UnitedHealth
UNH
$387B
$5.22M 3.45%
16,745
+3,850
+30% +$1.47M
MLYS icon
4
Mineralys Therapeutics
MLYS
$2.39B
$5.17M 3.42%
382,415
+11,902
+3% +$172K
CTNM
5
Contineum Therapeutics
CTNM
$532M
$3.18M 2.1%
800,787
– –
AMGN icon
6
Amgen
AMGN
$198B
$3.15M 2.08%
11,270
+885
+9% +$251K
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$123B
$3.09M 2.04%
6,945
+2,220
+47% +$1.02M
JNJ icon
8
Johnson & Johnson
JNJ
$609B
$2.95M 1.95%
19,300
-2,500
-11% -$384K
ISRG icon
9
Intuitive Surgical
ISRG
$122B
$2.85M 1.88%
5,250
– –
ABBV icon
10
AbbVie
ABBV
$450B
$2.75M 1.81%
14,800
– –
ORIC icon
11
Oric Pharmaceuticals
ORIC
$1.11B
$2.35M 1.55%
231,485
+211,485
+1,057% +$1.42M
BSX icon
12
Boston Scientific
BSX
$65.4B
$2.27M 1.5%
21,126
-3,100
-13% -$314K
ARGX icon
13
argenx
ARGX
$53.8B
$2.25M 1.49%
4,085
+982
+32% +$570K
MBX
14
MBX Biosciences
MBX
$2.99B
$2.19M 1.45%
+191,825
New +$1.95M
GILD icon
15
Gilead Sciences
GILD
$167B
$2.18M 1.44%
19,690
-12,330
-39% -$1.31M
PVLA
16
Palvella Therapeutics
PVLA
$2.26B
$2.16M 1.42%
+95,615
New +$2.24M
REPL icon
17
Replimune Group
REPL
$859M
$2.15M 1.42%
+231,650
New +$2.02M
RCUS icon
18
Arcus Biosciences
RCUS
$3.44B
$2.09M 1.38%
257,270
+230,400
+857% +$1.97M
DHR icon
19
Danaher
DHR
$144B
$2.09M 1.38%
10,575
– –
ABT icon
20
Abbott
ABT
$175B
$2.07M 1.36%
15,198
-3,500
-19% -$462K
SLDB icon
21
Solid Biosciences
SLDB
$858M
$2.05M 1.36%
+421,580
New +$1.49M
RAPP
22
Rapport Therapeutics
RAPP
$2.04B
$2.05M 1.35%
+179,860
New +$1.91M
ZBIO
23
Zenas BioPharma
ZBIO
$1.86B
$2.04M 1.35%
+210,625
New +$2.05M
VTYX
24
DELISTED
Ventyx Biosciences
VTYX
$1.99M 1.32%
+931,620
New +$1.5M
TECX
25
Tectonic Therapeutic
TECX
$615M
$1.97M 1.3%
+98,970
New +$2.01M
1
2 3 4 5

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
FWA
Fulcrum Wealth Advisors Bellevue, Washington $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM

Sectoral Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Sectoral Asset Management held 109 positions worth $151M, up 18% from $128M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sectoral Asset Management deployed $26.2M of net new capital in Q2 2025, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was Bicara Therapeutics: 201,395 shares worth $1.87M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $1.31M trimmed.

  • Sectoral Asset Management's largest Q2 2025 buy was Bicara Therapeutics: 201,395 shares worth $1.87M.
  • Sectoral Asset Management added most to Arcus Biosciences in Q2 2025, an estimated $1.97M increase.
  • Sectoral Asset Management's biggest Q2 2025 reduction was Gilead Sciences, cutting an estimated $1.31M.
  • Sectoral Asset Management fully exited Medtronic in Q2 2025, selling an estimated $2.14M.
  • Sectoral Asset Management's ten largest holdings make up 42% of its $151M portfolio in Q2 2025.
  • Sectoral Asset Management opened 25 new positions and closed 15 in Q2 2025.
  • Sectoral Asset Management's portfolio value rose 18% quarter-over-quarter to $151M.

Based on Sectoral Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.